Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2023 Results Conference Call February 27, 2024 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - EVP and Chief Commercial Officer Robert Wong - VP and Chief Accounting Officer Conference Call Participants Mayank Mamtani - B. Riley Securities Carter Gould - Barclays Paul Choi - Goldman Sachs Adi Jayanthi - JP Morga ...

Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.98%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.72 per share when it actually produced a loss of $1.35, delivering a surprise of -87.50%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...

CYTOKINETICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing Authorization Application to EMA in Q4 2024 Primary Results from SEQUOIA-HCM Are Expected to be Presented at an Upcoming Medical Conference in Q2 2024 Cardiac Muscle ...

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & ...

The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings. The wonderful and incredible treatments they have been creating lately have had a net positive impact on all of humanity. Furthermore, those that are in development have a promising future. Here are three biotech stocks to buy that you may want to consider adding to your ...

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations focused on the hypertrophic cardiomyopathy (HCM), heart failure and amyotrophic lateral sclerosis (ALS) communities. The gran ...

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM). In many patients with HCM, the left ventricular h ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations Robert Blum - President & Chief Executive Officer Fady Malik - Executive Vice President, Research & Development Stuart Kupfer - Vice President & Chief Medical Officer Andrew Callos - EVP & Chief Commercial Officer Robert Wong - Vice President & Chief Accounting Officer Ching Jaw - Senior Vice President ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-32913 ...